Dataset Information


Role of monoclonal antibody drugs in the treatment of COVID-19.

ABSTRACT: Currently clinicians all around the world are experiencing a pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical presentation of this pathology includes fever, dry cough, fatigue and acute respiratory distress syndrome that can lead to death infected patients. Current studies on coronavirus disease 2019 (COVID-19) continue to highlight the urgent need for an effective therapy. Numerous therapeutic strategies have been used until now but, to date, there is no specific effective treatment for SARS-CoV-2 infection. Elevated inflammatory cytokines have been reported in patients with COVID-19. Evidence suggests that elevated cytokine levels, reflecting a hyperinflammatory response secondary to SARS-CoV-2 infection, are responsible for multi-organ damage in patients with COVID-19. For these reason, numerous randomized clinical trials are currently underway to explore the effectiveness of biopharmaceutical drugs, such as, interleukin-1 blockers, interleukin-6 inhibitors, Janus kinase inhibitors, in COVID-19. The aim of the present paper is to briefly summarize the pathogenetic rationale and the state of the art of therapeutic strategy blocking hyperinflammation.

SUBMITTER: Ucciferri C 

PROVIDER: S-EPMC7559676 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7496634 | BioStudies
2020-01-01 | S-EPMC7583882 | BioStudies
2021-07-28 | PXD022990 | Pride
2020-01-01 | S-EPMC7484812 | BioStudies
2020-01-01 | S-EPMC7360379 | BioStudies
2020-01-01 | S-EPMC7548059 | BioStudies
2020-01-01 | S-EPMC7555368 | BioStudies
2020-01-01 | S-EPMC7204669 | BioStudies
2020-01-01 | S-EPMC7319213 | BioStudies
2020-01-01 | S-EPMC7734022 | BioStudies